Anavex up as co completes patient dosing in Rett syndrome drug trial

Anavex Life Sciences

06/06/2023 13:45

** Shares of drug developer Anavex Life Sciences Corp
 AVXL.O  up 1.2% at $9.17 premarket
    ** Co completes dosing of all participants in the
mid-to-late stage study of its treatment for pediatric patients
with Rett syndrome, a genetic brain disorder
    ** Co expects to report study results in H2
    ** The drug candidate has "Fast Track", "Rare Pediatric
Disease" and "Orphan Drug" designations from the FDA for the
treatment of Rett syndrome
    ** Co utilised FDA inputs related to study endpoints for the
trial
    ** Stock down 2% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))